Sparrow Pharmaceuticals
Sparrow Pharmaceuticals: Innovating targeted therapies for corticosteroid excess conditions.
Sparrow Pharmaceuticals: Innovating targeted therapies for corticosteroid excess conditions.
Founded with a mission to innovate targeted therapies for conditions of corticosteroid excess, Sparrow Pharmaceuticals focuses on addressing unmet needs in endocrinology and rheumatology. The company’s core product, SPI-62, is currently in Phase 2 clinical development and aims to treat endocrine disorders caused by the overproduction of cortisol. Leveraging proprietary HSD-inhibitor technology, Sparrow's approach combines clofutriben with prednisolone to offer a novel solution for patients suffering from the adverse effects of long-term corticosteroid use.
Sparrow Pharmaceuticals has attracted notable investors and industry experts who support its groundbreaking work in cellular biology and steroid management. Key achievements include advancing SPI-62 through critical clinical trial phases and gaining recognition for its innovative approach to treating cortisol-related conditions. The company's impact lies in its potential to revolutionize treatment protocols, offering new hope to patients who suffer from the debilitating effects of corticosteroid excess.
Companies similar to Sparrow Pharmaceuticals include Spiral Therapeutics, Corcept Therapeutics, Spruce Biosciences and Spyryx Biosciences.
Sparrow Pharmaceuticals was founded in 2013.
Sparrow Pharmaceuticals' headquarters is located in Portland, OR, US.
Sparrow Pharmaceuticals' most recent funding round was for $50M (USD) in May 2021.
As of May 18, 2021, Sparrow Pharmaceuticals has disclosed funding of $51.1M (USD). Undisclosed round amounts are excluded.
Sparrow Pharmaceuticals has 8 employees as of Feb 5, 2024.
Spyryx Biosciences
